Tissue Regenix announced that it has signed an exclusive distribution agreement with Joint Operations Ltd. for the distribution of the Tissue Regenix OrthoPure XT product in the United Kingdom. The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products. Joint Operations already distributes orthopedic equipment to the National Health Service and the private sector within the UK, offering clinicians comprehensive orthopedic solutions around joint reconstruction and preservation surgeries.

The OrthoPure XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL technology and is the only available, non-human biologic graft for certain anterior cruciate ligament reconstruction procedures on the market. OrthoPure XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.